Literature DB >> 9921950

Overexpression of endothelium-derived nitric oxide synthase isoform 3 in the vasculature of human pancreatic tumor biopsies.

A K Nussler1, S Gansauge, F Gansauge, U Fischer, U Butzer, P G Kremsner, H G Beger.   

Abstract

Cellular nitric oxide (NO) synthesis determines whether NO has cytoprotective or cytotoxic effects at anatomic sites; thus it is important to identify potential NO synthase isoforms in tumor tissue and tumor cell lines which might be involved in tumor development or destruction. Incubation of human pancreatic adenocarcinoma cell lines (AsPc-1, BxPc-3, CaPan-2) with cytokines resulted in increased NO formation, indicating the existence of the NOS2 isoform. This was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) and western blot analysis. Furthermore, we identified the presence of the endothelium-derived NOS isoform 3 by RT-PCR analysis and immunohistochemistry in normal and pancreatic tumor biopsies. NOS3 was markedly overexpressed in the vasculature of the tumor tissue. RT-PCR analysis of tumor biopsies identified NOS isoform 2 mRNA in 60% of cases, but western blot analysis or immunohistochemistry scored negative for this isoform. It is noteworthy that the NOS enzyme activity in pancreatic tumor cell lines and tumor biopsies was inhibited by EGTA by approximately 30% and 65%, respectively. Our results suggest that increased endothelium-derived NOS isoform 3 expression in pancreatic adenocarcinomas regulates blood flow and is therefore involved in the vascularization and neovascularization of human pancreatic tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9921950     DOI: 10.1007/s004230050163

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  6 in total

1.  Targeting eNOS in pancreatic cancer.

Authors:  Benjamin L Lampson; S Disean Kendall; Brooke B Ancrile; Meghan M Morrison; Michael J Shealy; Katharine S Barrientos; Matthew S Crowe; David F Kashatus; Rebekah R White; Susan B Gurley; Diana M Cardona; Christopher M Counter
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

2.  Quantitative measurement of iNOS expression in melanoma, nasopharyngeal, colorectal, and breast tumors of Tunisian patients: comparative study and clinical significance.

Authors:  Emna Dabbeche-Bouricha; Nadia Hadiji-Abbes; Rania Abdelmaksoud-Damak; Nesrine Alaya; Wajdi Ayadi; Slim Charfi; Abdelmajid Khabir; Tahia Sellami-Boudawara; Raja Mokdad-Gargouri
Journal:  Tumour Biol       Date:  2015-11-07

Review 3.  NO and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential.

Authors:  Jian Wang; S Perwez Hussain
Journal:  Antioxid Redox Signal       Date:  2016-09-22       Impact factor: 8.401

4.  eNOS Genetic Polymorphisms and Cancer Risk: A Meta-Analysis and a Case-Control Study of Breast Cancer.

Authors:  Xueren Gao; Jie Wang; Wenjun Wang; Mingxi Wang; Jianqiong Zhang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

5.  Role of nitric oxide in pancreatic cancer cells exhibiting the invasive phenotype.

Authors:  Mayumi Fujita; Veena Somasundaram; Debashree Basudhar; Robert Y S Cheng; Lisa A Ridnour; Harumi Higuchi; Kaori Imadome; Jae Hong No; Gaurav Bharadwaj; David A Wink
Journal:  Redox Biol       Date:  2019-03-06       Impact factor: 11.799

6.  Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines - a new strategy for therapy.

Authors:  Manida Suksawat; Anchalee Techasen; Nisana Namwat; Thianrut Boonsong; Attapol Titapun; Piti Ungarreevittaya; Puangrat Yongvanit; Watcharin Loilome
Journal:  FEBS Open Bio       Date:  2018-03-02       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.